. Бикбов Б.Т., Томилина Н.А. Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998–2011 гг. Отчет по данным Российского регистра заместительной почечной терапии. Часть первая. Нефрология и диализ. 2014; (1): 11–127.
Bikbov B.T., Tomilina N.A. Renal replacement therapy for ESRD patients in Russian Federation, 1998–2011. Report of Russian RRT Registry. Part 1. Nefrologiya i dializ = Nephrology and Dialysis. 2014; (1): 11–127.
2. Бикбов Б.Т., Томилина Н.А. Состав больных и показатели качества лечения на заместительной терапии терминальной хронической почечной недостаточности в Российской Федерации в 1998–2013 гг. Отчет по данным регистра заместительной почечной терапии Российского диализного общества. Часть вторая. Нефрология и диализ. 2016; 18 (2): 98–164.
Bikbov B.T., Tomilina N.A. The contingent and treatment quality indicators in patients on replacement therapy of end stage renal disease in the Russian Federation in 1998-2013 years. Report of the Register of Renal Replacement Therapy of the Russian Dialysis Society. Part II. Nefrologiya i dializ = Nephrology and Dialysis. 2016; 18 (2): 98–164.
3. Милованов Ю.С., Милованова Н.И. Нарушения нутритивного статуса при почечной недостаточности. М.: ГЭОТАР-Медиа, 2016.
Milovanov Yu.S., Milovanova N.I. Disorders of nutritional status in renal failure. Moscow: GEOTAR-Media, 2016.
4. Ртищева О.В., Калеев О.Ф. Возрастно-половые особенности показателей липидного обмена у больных, получающих лечение программным гемодиализом. Клин. нефрология. 2010; (4): 55–58.
Rtishcheva O.B., Kaleev O.F. Age-sex characteristics of lipid metabolism in patients receiving treatment with program hemodialysis. Klinicheskaya nefrologiya = Clinical Nephrology. 2010; (4): 55–58.
5. Al-Daghri N.M., Al-Attas O.S., Alokail M.S., Alkharfy KM., Charalampidis P., Livadas S., Kollias A., Sabico S.L., Chrousos G.P. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. Eur. J. Clin. Invest. 2013; 43 (2): 183–189. doi: 10.1111/eci.12030
6. Amato M.C., Giordano C., Galia M., Criscimanna A., Vitabile S., Midiri M., Galluzzo A., AlkaMeSy Study Group. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010; 33 (4): 920–922. doi: 10.2337/dc09-1825
7. Badve S.V., Paul S.K., Klein K., Clayton P.A., Hawley C.M., Brown F.G., Boudville N., Polkinghorne K.R., McDonald S.P., Johnson D.W. The association between body mass index and mortality in incident dialysis patients. PLoS One. 2014; 16; 9 (12): e114897. doi: 10.1371/journal.pone.0114897
8. Bevc S., Potočnic A., Hojs R. Lipids, waist circumference and body mass index in haemodialysis patients. J. Int. Med. Res. 2011; 39 (3): 1063–1074. doi: 10.1177/147323001103900341
9. Burmeister J.E., Mosmann C.B., Costa V.B., Saraiva R.T., Grandi R.R., Bastos J.P., Goncalves L.F., Rosito G.A. Prevalence of cardiovascular risk factors in hemodialysis patients – The CORDIAL study. Arq. Bras. Cardiol. 2014; 102 (5): 473–480. doi: 0.5935/abc.20140048
10. Chazot C., Deleaval P., Bernollin A.L., Vo-Van C., Lorriaux C., Hurot J.M., Mayor B., Jean G. Target weight gain during the first year of hemodialysis therapy is associated with patient survival. Nephron. Clin. Pract. 2014; 126 (3): 128–134. doi: 10.1159/000362211
11. Chen H.Y., Lin C.C., Chiu Y.L., Hsu S.P., Pai M.F., Yang J.Y., Peng Y.S. Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients. PLoS One. 2012; 7 (7): e38415. doi: 10.1371/journal.pone.0038415
12. Cordeiro A.C., Qureshi A.R., Lindholm B., Amparo F.C., Tito-Paladino-Filho A., Perini M., Lourenco F.S., Pinto I.M., Amodeo C., Carrero J.J. Visceral fat and coronary artery calcification in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2013; 28, Suppl. 4: iv152–iv159. doi: 10.1093/ndt/gft250
13. Cordeiro A.C., Qureshi A.R., Stenvinkel P., Heimburger O., Axelsson J., Barany P., Lindholm B., Carrero J.J. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol. Dial. Transplant. 2010; 25 (2): 562–568. doi: 10.1093/ndt/gfp492
14. DeNino W.F., Tchernof A., Dionne I.J., Toth M.J., Ades P.A., Sites C.K., Poehlman E.T. Contribution of abdominal adiposity to age-related difference in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 2001; 24 (5): 925–932. doi: 10.2337/diacare.24.5.925
15. Ferreira J.P., Couchoud C., Gregson J., Tiple A., Glowacki F., London G., Agarwal R., Rossignol P. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study. Nephrol. Dial. Transplant. 2019; 34 (7): 1216–1222. doi: 10.1093/ndt/gfy378
16. Heerspink H.J., Ninomiya T., Zoungas S., de Zeeuw D., Grobbee D.E., Jardine M.J., Gallagher M., Roberts M.A., Cass A., Neal B., Perkovic V. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009; 373 (9668): 1009–1015. doi: 10.1016/S0140-6736(09)60212-9
17. Honda H., Qureshi A.R., Axelsson J., Heimburger O., Suliman M.E., Barany P., Stenvinkel P., Lindholm B. Obese sarcopenia in patients with end-stage renal disease in associated with inflammation and increased mortality. Am. J. Clin. Nutr. 2007; 86 (3): 633–638. doi: 10.1093/ajcn/86.3.633
18. Ishimura E., Okuno S., Tsuboniwa N., Shoji S., Yamakawa T., Nishizawa Y., Inaba M. Relationship between fat mass and serum high-sensitivity C-reactive protein levels in prevalent hemodialysis patients. Nephron Clin. Pract. 2011; 119 (4): 283–288. doi: 10.1159/000328931
19. Kalantar-Zadeh K., Rhee C.M., Chou J., Ahmadi S.F., Park J., Chen J.L., Amin A.N. The obesity paradox in kidney disease: how to reconcile it with obesity management. Kidney Int. Rep. 2017; 2 (2): 271–281. doi: 10.1016/j.ekir.2017.01.009
20. Kato A., Ishida J., Endo Y., Takita T., Furuhashi M., Maruyama Y., Odamaki M. Association of abdominal visceral adiposity and thigh sacropenia with changes of arteriosclerosis in haemodialysis patients. Nephrol. Dial. Transplant. 2011; 26 (6): 1927–1976. doi: 10.1093/ndt/gfq652
21. Moriyama Y., Eriguchi R., Sato Y., Nakaya Y. Chronic hemodialysis patients with visceral obesity have a higher risk for cardiovascular events. Asia Pac. J. Clin. Nutr. 2011; 20 (1): 109–117.
22. Neeland I.J., Turer A.T., Ayers C.R., Powell-Wiley T.M., Vega G.L., Farzaneh-Far R., Grundy S.M., Khera A., McGuire D.K., de Lemos J.A. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012; 308 (11): 1150–1159. doi: 10.1001/2012.jama.1113
23. Noori N., Kovesdy C.P., Dukkipati R., Kim Y., Duong U., Bross R., Oreopoulos A., Luna A., Benner D., Kopple J.D., Kalantar-Zadeh K. Survival predictability of lean and fat mass in men and women undergoing maintenance hemodialysis. Am. J. Clin. Nutr. 2010; 92 (5): 1060–1070. doi: 10.3945/ajcn.2010.29188.
24. Odamaki M., Furuya R., Ohkawa S. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol. Dial. Transplant. 1999; 14 (10): 2427–2432.
25. Ohkawa S., Odamaki M., Ikegaya N., Hibi I., Miyaji K., Kumagai H. Association of age with muscle mass, fat mass and fat distribution in non-diabetic haemodialysis patients. Nephrol. Dial. Transplant. 2005; 20: 945–951. doi: 10.1093/ndt/gfh643
26. Okamoto T., Hatakeyama S., Kodama H., Horiguchi H., Kubota Y., Kido K., Momota M., Hosogoe S., Tanaka Y., Takashima T., Saitoh F., Suzuki T., Ohyama C. The relationship between poor nutritional status and progression of aortic calcification in patients on maintenance hemodialysis. BMC Nephrol. 2018; 19 (1): 71. doi: 10.1186/s12882-018-0872-y
27. Panzetta G., Abaterusso C. Obesity in dialysis and reverse epidemiology: true or false? G. Ital. Nefrol. 2010; 27 (6): 629–638.
28. Portoles J., Lopez-Gomez J.M., Aljama P. Riesgo cardiovascular en hemodialisis enEspana: prevalencia, pautas de actuacion yobjetivos (estudio MAR). Nefrologia. 2005; 25 (3): 297–306.
Portoles J., Lopez-Gomez J.M., Aljama P. Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study). Nefrologia = Nephrology. 2005; 25 (3): 297–306. [In Spain].
29. Postorino M., Marino C., Tripepi G., Zoccali C., CREDIT (Calabria Registry of Dialysis and Transplantation) Working Group. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J. Am. Coll. Cardiol. 2009: 53 (15): 1265–1272. doi: 10.1016/j.jacc.2008.12.040
30. Ryo M., Kishida K., Nakamura T., Yoshizumi T., Funahashi T., Shimomura I. Clinical significance of visceral adiposity assessed by computed tomography: A Japanese perspective. World J. Radiol. 2014; 6 (7): 409–416. doi: 10.4329/wjr.v6.i7.409
31. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., McCullough P.A., Kasiske B.L., Kelepouris E., Klag M.J., Parfrey P., Pfeffer M., Raij L., Spinosa D.J., Wilson P.W. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108 (17): 2154–2169. doi: 10.1161/01.CIR.0000095676.90936.80
32. Yurugi T., Morimoto S., Okamoto T., Amari Y., Kasuno Y., Fukui M., Nakajima F., Nishikawa M., Iwasaka T. Accumulation of visceral fat in maintenance hemodialysis patients. Clin. Exp. Nephrol. 2012; 16 (1): 156–163. doi: 10.1007/s10157-011-0544-8
